Deal bolsters manufacturing capacity and capabilities.

PolyPeptide Laboratories is acquiring NeoMPS from Isochem. NeoMPS, a peptide manufacturer, operates two facilities one in Strasbourg, France, and one in San Diego. The takeover bolsters PolyPeptide Laboratories’ manufacturing capacity and capabilities, from small-scale custom peptides for research to large-scale peptides for therapeutic applications.


NeoMPS also manufactures cosmetic peptides and brings an extensive catalog business to PolyPeptide Laboratories, according to the company.


“The addition of NeoMPS to the PolyPeptide Laboratories Group is a great fit and offers customers of both companies an even more comprehensive range of services for every stage of development,” says Jane Salik, CEO of PolyPeptide Laboratories. “With this acquisition, we are expanding our capacity to meet the needs of customers who demand the most robust, scalable, and cost-efficient peptide manufacturing available.”


With the NeoMPS acquisition, PolyPeptide Laboratories will now operate GMP facilities in two locations in California; Strasbourg; Hillerod, Denmark; and Malmo, Sweden. In addition, a new GMP facility is being constructed in Mumbai, India, that will be focused on generic peptides.

Previous articleMIT and Indian Government Partner to Establish Health and Science Institute
Next articleCelgene to Acquire Pharmion for $2.9B